Tier 1 — highest
Creatine and improvement in cognitive function: Evaluation of a health claim pursuant to article 13(5) of regulation (EC) No 1924/2006
EFSA J
2024
22(11):e9100
Bibliography
- PubMed
- PMID 39564533
- PubMed Central
- PMC11574456
- Funding
- EFSA scientific opinion produced following a health-claim application submitted by Alzchem Trostberg GmbH; this is a regulatory evidence assessment, not a supplementation trial.
- Competing interests
- This record represents an EFSA panel scientific opinion. Biohack Blueprint treats the applicant's commercial interest and the independent regulatory assessment as separate parts of the evidence context.
Study snapshot
| Design | Regulatory scientific evidence assessment |
|---|---|
| Model | Human intervention evidence |
| Sample | 21 applicant-identified human intervention studies plus 2 additional studies identified from a meta-analysis reference list |
| Intervention | Creatine supplementation across human cognition studies |
| Duration | Varied by included study |
| Endpoints | Working memory; Response inhibition; Cognitive domains; Mechanistic plausibility |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Creatine Brain Benefits: Memory, Cognition, Sleep Loss and What Is Still UncertainCreatine and the brain: evidence for memory, attention, processing speed, older adults and stressed states—plus why recent systematic reviews disagree.Read analysis
- Creatine Benefits: Strength, Muscle, Brain and Healthy Aging EvidenceThe benefits of creatine separated by evidence strength: strength, lean mass, performance, women, older adults and cognition.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
